Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tandem, Bispecific Anti-CD19 Anti-CD20 CAR-T Cells in Relapsed/Refractory B Cell Malignancies
NCT04186520Phase 2Recruiting
- Sponsor
- Medical College of Wisconsin
- Start
- May 2020
- Primary completion
- Feb 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of zamtocabtagene autoleucel in B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), central nervous system lymphoma, sponsored by Medical College of Wisconsin. Started May 2020; status: recruiting.
02
Drugs
zamtocabtagene autoleucel
03
Conditions
B-cell non-Hodgkin lymphomachronic lymphocytic leukemia (CLL)mantle cell lymphoma (MCL)central nervous system lymphoma
Beyond the preview
Go deeper on NCT04186520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04186520.